Camden Capital, LLC Tg Therapeutics, Inc. Transaction History
Camden Capital, LLC
- $1.14 Billion
- Q1 2024
Shares
2 transactions
Others Institutions Holding TGTX
# of Institutions
269Shares Held
87.7MCall Options Held
2.72MPut Options Held
1.74M-
Vanguard Group Inc Valley Forge, PA13.5MShares$257 Million0.0% of portfolio
-
Black Rock Inc. New York, NY10.8MShares$206 Million0.0% of portfolio
-
State Street Corp Boston, MA7.8MShares$148 Million0.01% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.48MShares$66.2 Million0.02% of portfolio
-
Pictet Asset Management Holding Sa Carouge, V83.33MShares$63.3 Million0.06% of portfolio
About TG THERAPEUTICS, INC.
- Ticker TGTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 145,274,000
- Market Cap $2.76B
- Description
- TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...